*To the Editor*:

"Cytokine storm", inflammation-mediated severe lung damage and defective haemostasis are the main underlying reasons for morbidity and mortality in coronavirus disease 2019 (COVID-19) patients \[[@C1]\]. Several immunotherapies that target various inflammatory processes have been successfully used in COVID-19 patients and many other strategies are under evaluation \[[@C2], [@C3]\]. However, in view of dysregulated immune responses in severe COVID-19 patients, we suggest that CD4^+^CD25^+^FoxP3^+^ regulatory T-cell (Treg)-based strategies could be considered for patient management.

Vigorous antimicrobial responses triggered against the pathogen can be detrimental to the host due to collateral tissue damage. Therefore, regulatory mechanisms, and in particular Tregs, are in place to ensure that inflammation is kept in check. Tregs are either thymus-derived or induced in the periphery and are classically known for stimulating immune tolerance, and preventing autoimmune and inflammatory diseases \[[@C4]\]. Tregs inhibit the activation of both innate and adaptive immune cells *via* inhibitory surface molecules (like cytotoxic T-lymphocyte antigen-4 (CTLA-4) and lymphocyte-activation gene-3) and secretion of immunosuppressive cytokines (interleukin (IL)-10, transforming growth factor-β and IL-35). Both Treg subsets are equally important to prevent inflammation-induced tissue damage during acute infections and to promote tissue repair, which is particularly shown in the influenza infection model \[[@C4], [@C5]\].

The current evidence suggests that the level of peripheral Tregs is prominently reduced in severely ill COVID-19 patients compared with mild patients \[[@C6]--[@C9]\]. Though the reasons for reduced frequency of Tregs in peripheral blood are not completely understood, one of the possibilities is that Tregs might have migrated to the lungs to prevent tissue damage. Detailed investigation of Tregs in the lung tissues of severe COVID-19 patients and their molecular signatures would provide insight on these questions. However, *in silico* analyses performed on the transcriptomic data of CD4^+^ T-cells from the COVID-19 patient\'s bronchoalveolar lavage suggest that *IL2* transcripts were reduced in severe cases compared with mild cases \[[@C10]\]. Therefore, reduced *IL2* would lead to enhanced apoptosis of Tregs and is also confirmed by reduced levels of *FoxP3*. Moreover, severe COVID-19 patients have increased levels of soluble IL-2R (CD25) \[[@C6]--[@C8]\], probably due to inflammation-induced enhanced proteolytic cleavage of cell surface CD25. This soluble CD25 could potentially interfere with IL-2 bioavailability and signalling, and hence might further promote apoptosis of Tregs. It has also been shown that Middle East respiratory syndrome coronavirus could infect T-cells \[[@C11]\] and hence, a direct effect of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on the biology of Tregs cannot be ruled out.

Considering the importance of Tregs in immune homeostasis, reduction in the levels of Tregs could be one of the reasons for the hyperactivated immune system and damaged lungs in severe COVID-19 patients. It is worth noting that depletion of Treg from the mice infected with murine coronavirus lead to increased mortality with acute encephalitis, thus highlighting the protective nature of Tregs during acute coronavirus infection \[[@C12]\]. It should also be noted that obesity is one of the risk factors for COVID-19, and data from obese subjects and pertinent animal models have shown that Tregs in the circulation and visceral adipose tissues are decreased compared with those in lean subjects, and consequently there is a higher state of inflammation and insulin resistance \[[@C13], [@C14]\].

Given the dysregulated immune response in severe COVID-19 patients, we propose that Tregs have therapeutic potential in patient management. Adoptive transfer of *ex vivo* expanded polyclonal Tregs has recently been used to treat autoimmune and inflammatory diseases \[[@C15]\]. But polyclonal Treg therapy is time consuming, requiring nearly 2 weeks to expand sufficient quantities of viable clinical-grade Tregs for immunotherapy. However, unlike autoimmune diseases, COVID-19 patients need an instant therapy to prevent morbidity and mortality. Therefore, adoptive transfer autologous polyclonal Treg therapy is not a viable option in COVID-19 patients. Also, the approach is not economically feasible for an infectious disease. Alternatively, allogeneic human leukocyte antigen-matched umbilical cord-derived Tregs are under exploration for inflammatory conditions (ongoing clinical trials registered at ClinicalTrials.gov: NCT02932826 and NCT03011021) ([figure 1](#F1){ref-type="fig"}) \[[@C16]\]. In view of the drawbacks of autologous Treg therapy, allogeneic-matched cord Tregs could be considered for severe COVID-19 patients. Of late, two COVID-19 patients with acute respiratory distress syndrome (ARDS) were treated twice or thrice with allogeneic, off-the-shelf, cord-blood derived, *ex vivo* expanded Tregs (1 × 10^8^ cells per dose). The Treg therapy was associated with rapid decline in the various inflammatory mediators including IL-6, TNF-α, IFN-γ, IL-8 and IL-12 \[[@C17]\].

![Potential of regulatory T-cell (Treg)-based therapies in the management of severe coronavirus disease 2019 (COVID-19). Tregs and their functions are compromised in severe COVID-19 patients, engendering unrestrained immune cell activation. Dysregulated antigen-presenting cells (APCs) insinuate tissue inflammation and immunopathology by secreting inflammatory cytokines and activating a T-cell-dependent immune response. We suggest that either adoptive transfer of allogenic Tregs or use of Treg-derived molecules like cytotoxic T-lymphocyte antigen (CTLA)-4 (abatacept) might block the activation of APC and costimulatory pathways. Such therapies have the potential to curtail tissue inflammation and immunopathology, leading to better management of COVID-19 patients. IL: interleukin; TNF: tumour necrosis factor.](ERJ-02182-2020.01){#F1}

Another strategy is to boost Tregs *in vivo*. Low-dose IL-2 has been used to specifically induce Treg expansion *in vivo* in type 1 diabetes, and other autoimmune and inflammatory diseases \[[@C18]\]. The high affinity of CD25 towards IL-2 would lead to selective Treg expansion. But severe COVID-19 patients display increased levels of soluble IL-2R \[[@C6]--[@C8]\] that could potentially scavenge IL-2. Other reports have demonstrated that severe COVID-19 patients have increased IL-2 levels \[[@C1]\] and despite having higher IL-2, Tregs were lower in severe COVID-19 patients. All these arguments suggest that low-dose IL-2 therapy might not be beneficial in COVID-19 patients. Nevertheless, a clinical trial is planned with low-dose IL-2 for acute respiratory distress syndrome related to COVID-19 (trial NCT04357444 registered at ClinicalTrials.gov). Data from this trial will provide valuable information on the feasibility of this strategy not only for COVID-19 but also for other acute viral diseases. Other Treg expansion strategies, like IL-2 complexed with monoclonal antibodies to selectively trigger Treg activation \[[@C19]\] or to induce STAT5 phosphorylation and Treg expansion \[[@C20]\], have been explored in pre-clinical models. But they have yet to be tested in clinic and in view of their unproven efficacy in patients, it is too risky to use them in COVID-19 patients.

In view of various shortcomings with either adoptive Treg therapy or *in vivo* Treg expansion strategies, therapy with Treg-derived immunoregulatory molecules, in particular CTLA-4, might hold the potential for controlling inflammation in severe COVID-19 patients ([figure 1](#F1){ref-type="fig"}). At cellular level, CTLA-4 interacts with B7 family members (CD80 and CD86) on innate cells. Through trans-endocytosis and degradation of B7 molecules inside CTLA-4-expressing cells, CTLA-4 reduces co-stimulatory signals for T-cells \[[@C21]\]. The recombinant Fc-fused CTLA-4 protein abatacept has been used for several years for the immunotherapy of systematic autoimmune diseases. Though our knowledge on the mechanisms of this fusion protein is still incomplete, current literature suggest that by interacting with B7 molecules on antigen-presenting cells, abatacept interferes with CD28-mediated T-cell signalling and activation \[[@C22]\]. Abatacept might also affect the activation of innate cells, such as monocytes and dendritic cells, and enhance Tregs, though data on the Treg function are limited and conflicting \[[@C23], [@C24]\].

While data is not available regarding abatacept therapy in COVID-19 patients, recent longitudinal observational studies on the incidence of COVID-19 in abatacept-treated patients provide a pointer towards its therapeutic potential in severely ill COVID-19 patients. An epidemiological survey performed in the large tertiary hospital in Barcelona (Spain) indicated that abatacept-treated patients (42 patients from a cohort of 959 patients treated with biological and synthetic disease-modifying anti-rheumatic drugs (DMARD)) exhibited the lowest frequency of COVID-19-compatible symptoms \[[@C25]\]. Similar data were also obtained from a hospital in Madrid (Spain), where it was noted that none of the 27 abatacept-treated patients (among 802 DMARD-treated patients) were admitted to hospital with COVID-19 symptoms \[[@C26]\]. Furthermore, among 779 biological DMARD-treated patients from Siena (Italy), only two tested positive for COVID-19 and notably none of the 55 abatacept-treated patients in this cohort experienced COVID-19 \[[@C27]\].

Although these observations are from small cohorts and it is possible that the patients were practicing strict social distancing, the data on abatacept-treated patients are not surprising in view of its documented clinical benefits in autoimmune diseases \[[@C28]\] and the mechanisms of action of CTLA-4 to mitigate inflammatory responses.

Various immunotherapies that target the cytokine storm and prevent lung damage have gained prominence in the management of severe COVID-19 patients. Among the Treg-based therapeutic approaches, CTLA-4-based therapies appear to be attractive to overcome the hyperinflammatory state of severely ill COVID-19 patients. Clinicaltrials.gov registry shows that 47 studies are registered for the evaluation of tocilizumab (a humanised monoclonal antibody to IL-6 receptor α)/sarilumab (a fully human monoclonal antibody to IL-6 receptor α) in COVID-19 patients and 14 studies are registered for anakinra (an IL-1 receptor antagonist). However, just a single Phase 2 clinical trial has been registered recently for abatacept therapy in COVID-19 patients (trial NCT04472494 registered at ClinicalTrials.gov). Initial clinical trials mainly focused on the management of the cytokine storm and in particular, the role of IL-6 and IL-1β. Data on the Tregs in COVID-19 patients were also scarce during the early period of the COVID-19 pandemic. These points may explain why abatacept is yet to be considered for the management of COVID-19 patients, apart from the recently registered clinical trial (NCT04472494). As more data emerge on the fate of Tregs in COVID-19 patients, the aforementioned clinical observations could be taken as a basis for initiating randomised trials on CTLA-4-Fc (abatacept) therapy in moderate or severe COVID-19 patients. Though abatacept therapy in autoimmune patients is not associated with a predisposition to infection, selection of the dosage and the window of treatment are critical to strike a balance between inflammation and protective immune response to SARS-CoV-2. We believe that early treatment with abatacept might not benefit COVID-19 patients as it would curtail effective protective immune responses against SARS-CoV-2. For the initial exploration, the treatment regimen adapted for the tocilizumab therapy of COVID-19 patients or even the abatacept regimen used in DMARD treatment of rheumatic diseases could be considered.
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